defined term means any capitalized term that is defined in this Section 1.1 of the Plan.
defined term. Section: “Mxxxxx Sxxxxxx” 7.2(t) “Multi-Employer Plan” 7.1(i)(ii) “Newco” RECITALS “Newco Contribution Shares” 3.1(d) “Newco Governing Instruments” 2.1 “Newco Governmental Authorizations” 3.1(b)(xiv) “Newco Indemnified Persons” 12.3 “Order” 10.1(e) “PBGC” 7.1(i)(iii) “Preferred Stock” 2.1 “Proxy Statement/Prospectus” 7.1(f) “Qualifying Acquisition Proposal” 9.1 “Registration Statement” 7.1(f) “Representative” 9.1 “Required Governmental Authorizations” 10.1(c) “Revised Terms” 9.1(c) “Rights Agreement” 7.1(b) “Section 16 Information” 9.12 “Stratex” PREAMBLE “Stratex Audit Date” 7.1(e) “Stratex Award” 6.4(b) “Stratex Benefit Plans” 7.1(i)(i) “Stratex Budget” 8.1(c) “Stratex Bylaws” 7.1(a) “Stratex Certificate” 7.1(a) “Stratex Disclosure Letter” 7.1 “Stratex ERISA Affiliate” 7.1(i)(iii) “Stratex ERISA Plans” 7.1(i)(ii) “Stratex Governing Instruments” 7.1(a) “Stratex IP Contracts” 7.1(o)(ii)(A) Defined Term: Section: “Stratex IP Rights” 7.1(o)(ii)(B) “Stratex Material Contracts” 7.1(q)(ii) “Stratex Networks, Inc.” 4.1 “Stratex Option” 6.4(a) “Stratex Pension Plan” 7.1(i)(ii) “Stratex Preferred Stock” 7.1(b) “Stratex Reports” 7.1(e) “Stratex Required Third Party Consents” 10.2(e) “Stratex Requisite Vote” 7.1(c) “Stratex Stock Plans” 7.1(b) “Stratex Stockholders Meeting” 9.3(f) “Stratex Transactions” 7.1(c) “Superior Proposal” 9.1 “Surviving Corporation” 3.2 “Tail Period” 11.2(b) “Takeover Statute” 7.1(k) “Termination Date” 11.1(b) “Termination Fee” 11.2(b) “Third-Party IP Rights” 7.1(o)(ii)(B) “Transactions” 2.1 “Transfer” 3.1 “Voting Agreements” RECITALS “Voting Debt” 7.1(b) “Warrant Agreement” 6.5
defined term. Effective Date" set forth in Section 1.1 of the Deed of Trust is hereby deleted in its entirety.
More Definitions of defined term
defined term. Revolving Facility" set forth in Article I of the Agreement is hereby amended to read, in its entirety, as follows:
defined term means words or phrases which are defined or explained in clause 39.1.
defined term. Loans" set forth in Section 1.1 of the Deed of Trust is hereby amended in its entirety to provide as follows:
defined term. Originator" appearing in Section 1.1 of the Loan Agreement is amended in its entirety to be and to read as follows: "Originator" shall mean each of the following Delaware corporations: Borg- Warner Automotive Diversified Xxxxxxxxxxxn Products Corporation; Borg-Warner Automotive Air/Fluid Syxxxxx Xxxxxration; Borg-Warner Automotive Morse TEC Coxxxxxxxxx; Borg-Warner Xxxxxotive Automatic Trxxxxxxxxxx Systems Corporation; and Borg-Warner Automotive Powertrain Sxxxxxx Xxxxoration, Borg-Warner Automotive Turbo Systemx Xxxxxxxxxon and Borg-Warner Automotive Fuel Systems Xxxxxxxxxxn.
defined term. Subleased Premises" shall mean no less than 62,000 and not more than 64,000 rentable square feet of space located on the first, third and fourth floor(s) of the approximately 100,000 square foot building at 000 Xxxxxxxxx Xxxxx, Xxxxxxxxxx, Xxx Xxxxxxxxx (the "Building"). After completion of the Leasehold Improvement Work, Sublessor shall provide Sublessee with a certified measurement of the rentable space within 60 days from the date of Sublessee's occupancy of the Subleased Premises and the appropriate Lease provision shall automatically be amended consistent therewith.
defined term. Warrant" as used in the Warrant shall mean the Warrant as amended by any amendments to the Warrant, and any warrants issued in exchange or replacement of the Warrant or upon the transfer of the Warrant hereof.
defined term. Section: Additional Study 2.2.6(c) Adverse Study Effect 2.2.6(c)(3) [***] 5.4.1(b) [***] 5.4.1(a) [***] 2.2.7 Celgene Preamble Celgene Corp. Preamble Celgene Licensed Product Data 1.13 Celgene Switzerland Preamble [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Defined Term: Section: [***] 3.3.2 Commercialization Opt-In Activities Exhibit F Commercialization Report 3.4.4 Cure Period 9.3.1 Floor Royalty 5.4.3 Indemnification Claim 8.3 Indemnitee 8.3 Indemnitor 8.3 [***] 5.5.3 Juno Preamble Juno Licensed Product Data 1.13 Juno Reversion Products 9.8.1 [***] Exhibit C-1 License Agreement Preamble License Agreement Effective Date Preamble License Competitive Infringement 6.5.1 License Covering Patent 6.6.1 License Enforcement Proceeding 6.5.2(h) License Material Transfer Agreement 2.6.1 License Material Transfer Agreement Effective Date Exhibit E License Materials 2.6.1 License Materials Receiving Party 2.6.1 License Purpose 2.6.1 License Selling Party 1.10 License Step-In Proceeding 6.5.2(h) License Term 9.1.1 License Third Party Payment 6.10 License Transferring Party 2.6.1 Licensed Candidates Exhibit B Licensed Diagnostic Product 1.5 Licensed Product Patents 6.5.2(a) Licensed Program Exhibit A Licensed Program Assets 2.8 Licensed Target Exhibit B Master Collaboration Agreement Recitals [***] 3.3.2 Non-Proposing Party 2.2.6(c)(1) Other Actives 1.11